- Market Capitalization, $K 1,407,132
- Shares Outstanding, K 68,142
- Annual Sales, $ 103,540 K
- Annual Income, $ -42,800 K
- 60-Month Beta N/A
- Price/Sales 13.31
- Price/Cash Flow N/A
- Price/Book 4.29
|Period||Period Low||Period High||Performance|
| || |
+2.03 (+11.12%)since 04/27/20
| || |
+2.61 (+14.76%)since 02/27/20
| || |
+5.34 (+35.72%)since 05/24/19
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Wednesday reported a loss of $19.1 million in its first quarter.
SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Tuesday reported a loss of $15.9 million in its fourth quarter.
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
The biotech sector was in focus with pipeline updates from a few small biotech companies.
NEW YORK (AP) — Stocks that moved heavily or traded substantially on Monday:
Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that...
USA News Group - A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that may also suppress Zika virus infection. Zika virus disease...
|Ngm Biopharmaceuticals Inc|
|Raymond James Sb-1 Equity Invesco ETF|
|U.S. Liquidity Factor Vanguard ETF|
|Nasdaq Biotechnology Ishares ETF|
|Russell 2000 Growth Ishares ETF|
|Russell 2000 Growth Vanguard|